Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.
The DOI matches its Crossref record.
Abstract
9018 Background: NIVO is a programmed death-1 (PD-1) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in pts with MEL. The objective of the current analysis is to describe the safety profile of NIVO across recent MEL studies, including 4 studies in which guidelines for the management of adverse events (AEs) were utilized. Methods: A retrospective safety review was conducted for 4 ongoing phase I–III trials, in which MEL pts received NIVO 3 mg/kg Q2W until disease progression or unacceptable toxicity. Data were included from pts who received at least 1 dose of NIVO, and included assessments of AEs, select AEs (immune-related etiology), time to onset and resolution, and the use as well as impact of immune modulating agents (IMs). Results: A total of 576 patients received NIVO for a median of 3.7 months; 312 (54%) had received prior ipilimumab (IPI). The most frequent drug-related AEs of any grade were fatigue (25%), pruritus (17%), diarrhea (13%), and rash (13%); grade 3–4 drug-related AEs occurred in 10% of all pts, and in 8% of pts with prior IPI. No drug-related deaths were reported. Drug-related select AEs of any grade were most frequent in the skin (34%), GI tract (13%), endocrine glands (8%) and liver (4%); grade 3–4 select AEs occurred in 4% of pts. Median time to onset of drug-related select AEs ranged from 5 wks for skin AEs to 15 wks for renal AEs. IMs were administered to 166/474 pts (35%) in phase III studies to manage AEs; 114 pts (24%) received systemic corticosteroids. Among 21 pts with grade 3–4 drug-related select AEs, all but 1 pt with a skin AE resolved with IMs. Median time to resolution ranged from 3 wks for hepatic AEs to 29 wks for skin AEs. The objective response rate was 44% in pts who received an IM and 36% in those who did not; time to response was similar (median 9 wks), and the median duration of response was not reached for either pt subgroup. Conclusions: In this pooled analysis, drug-related AEs with NIVO monotherapy were primarily low grade and the incidence of grade 3–4 drug-related AEs was not affected by prior IPI. Nearly all drug-related grade 3–4 select AEs resolved with use of IMs, which did not appear to impact on tumor response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Self-citationToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Self-citationManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Self-citationFreeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
“The primary objectives of this study were to assess the safety and tolerability of nivolumab in combination with or without a peptide vaccine in HLA-A 0201–positive subjects, and overall safety and clinical results have been previously reported elsewhere (28).”
BackgroundSelf-citation
Metadata
- Authors
- Weber, J. S., Antonia, S. J., Topalian, S. L., Schadendorf, D., Larkin, J. M. G., Sznol, M., Liu, H. Y., Waxman, I., & Robert, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-05-20
- Volume
- 33
- Issue
- 15_suppl
- Pages
- 9018-9018
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2313175236
- Cited by
- 103
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.9018
- The paper
- Weber, J. S., Antonia, S. J., Topalian, S. L., Schadendorf, D., Larkin, J. M. G., Sznol, M., Liu, H. Y., Waxman, I., & Robert, C. (2015). Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.9018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.